Capital Expenditures for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current capital expenditures (TTM) is $898.40M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingCapital ExpendituresSwitch metric
Latest period
$898.40M
YoY change
+18.9%
5Y CAGR
+7.9%
Peak year (2023)
$926.40M
Cumulative capital expenditures
$7.59B
CapEx history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
CapEx history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $898.40M | +18.9% | ||
| 2024 | $755.90M | -18.4% | ||
| 2023 | $926.40M | +57.0% | ||
| 2022 | $590.10M | +6.9% | ||
| 2021 | $551.90M | -10.2% | ||
| 2020 | $614.60M | +43.1% | ||
| 2019 | $429.60M | +12.1% | ||
| 2018 | $383.10M | +40.5% | ||
| 2017 | $272.60M | -46.7% | ||
| 2016 | $511.90M | -24.5% | ||
| 2015 | $677.93M | +103.6% | ||
| 2014 | $333.01M | +113.0% | ||
| 2013 | $156.32M | +216.8% | ||
| 2012 | $49.34M | -13.8% | ||
| 2011 | $57.22M | -42.6% | ||
| 2010 | $99.69M | +2.4% | ||
| 2009 | $97.32M | +179.2% | ||
| 2008 | $34.86M | +89.0% | ||
| 2007 | $18.45M | +556.2% | ||
| 2006 | $2.81M | -43.4% | ||
| 2005 | $4.96M | -19.6% | ||
| 2004 | $6.17M | -79.2% | ||
| 2003 | $29.66M | -13.7% | ||
| 2002 | $34.37M | +318.0% | ||
| 2001 | $8.22M | +26.6% | ||
| 2000 | $6.50M | +13.9% | ||
| 1999 | $5.70M | +90.0% | ||
| 1998 | $3.00M | +42.9% | ||
| 1997 | $2.10M | -75.6% | ||
| 1996 | $8.60M | +160.6% | ||
| 1995 | $3.30M | -52.2% | ||
| 1994 | $6.90M | -32.4% | ||
| 1993 | $10.20M | +385.7% | ||
| 1992 | $2.10M | +110.0% | ||
| 1991 | $1.00M | — |
CapEx values are taken from Regeneron Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Regeneron Pharmaceuticals (REGN) most recent annual capital expenditures stands at $898.40M (2025) – grew 18.9% year-over-year.
Regeneron Pharmaceuticals capital expenditures compound annual growth for the 2020–2025 (5 years) window is +7.9%, with the latest reading among the more recent periods of the dataset.
Regeneron Pharmaceuticals capital expenditures edged down from $926.40M in 2023 to $898.40M in 2025, a 3.0% drawdown.
Across the available history, capital expenditures reached its high of $926.40M in 2023 and its low of $1.00M in 1991.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 9th; the peer median for capital expenditures is $3.87B.
Regeneron Pharmaceuticals Capital Expenditures by Year
Regeneron Pharmaceuticals Capital Expenditures 2025: $898.40M
Regeneron Pharmaceuticals capital expenditures in 2025 was $898.40M, grew 18.9% from 2024.
Regeneron Pharmaceuticals Capital Expenditures 2024: $755.90M
Regeneron Pharmaceuticals capital expenditures in 2024 was $755.90M, declined 18.4% below 2023.
Regeneron Pharmaceuticals Capital Expenditures 2023: $926.40M
Regeneron Pharmaceuticals capital expenditures in 2023 was $926.40M, surged 57.0% from 2022. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Capital Expenditures 2022: $590.10M
Regeneron Pharmaceuticals capital expenditures in 2022 was $590.10M, grew 6.9% from 2021.
Regeneron Pharmaceuticals Capital Expenditures 2021: $551.90M
Regeneron Pharmaceuticals capital expenditures in 2021 was $551.90M.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — CapEx
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's capital expenditures?
- Latest reported capital expenditures for Regeneron Pharmaceuticals (REGN) is $898.40M (period ending December 31, 2025).
How has Regeneron Pharmaceuticals capital expenditures changed year-over-year?
- Regeneron Pharmaceuticals (REGN) capital expenditures changed +18.9% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals capital expenditures?
- Regeneron Pharmaceuticals (REGN) capital expenditures compound annual growth rate is +7.9% over the most recent 5 years available.
When did Regeneron Pharmaceuticals capital expenditures hit its highest annual value?
- Regeneron Pharmaceuticals capital expenditures reached its highest annual value of $926.40M in 2023.
What was Regeneron Pharmaceuticals capital expenditures in 2024?
- Regeneron Pharmaceuticals (REGN) capital expenditures in 2024 was $755.90M.
What was Regeneron Pharmaceuticals capital expenditures in 2025?
- Regeneron Pharmaceuticals (REGN) capital expenditures in 2025 was $898.40M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.